The compounds and suppliers used in the experiments described throughout the manuscript were: sodium pentobarbital (Dolethal®; Vetoquinol, Madrid, Spain); heparin sodium from Rovi (Madrid, Spain); atropine sulphate (Scharlau, Barcelona, Spain); indomethacin (Acofarma, Barcelona, Spain); alloxan monohydrate, 1-PBG, BRL-54443 maleate salt, glibenclamide, NA bitartrate, and 5-HT hydrochloride (Merck Life Sciences S.L.U., Madrid, Spain); 5-CT, 8-OH-DPAT, α-methyl-5-HT, AS-19, cisapride, CGS-12066B, L-694,247, LY310762 hydrochloride, ODQ, and SB 699551 (Tocris Bioscience, Bristol, UK).
All the compounds were dissolved in saline at the time of experimentation, except AS-19 (dissolved in EtOH 5%), cisapride (0.01 M HCl), and both indomethacin and glibenclamide (dissolved in a mixture of PEN). None of the vehicles alter either RPP or SBP.
All the compounds were dissolved in saline at the time of experimentation, except AS-19 (dissolved in EtOH 5%), cisapride (0.01 M HCl), and both indomethacin and glibenclamide (dissolved in a mixture of PEN). None of the vehicles alter either RPP or SBP.